15 results about "Ganglioside" patented technology

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

The present invention relates to the field of biotechnology and immunooncology. The invention discloses a bispecific antibody. The bispecific antibody comprises an antibody, an antibody fragment or a single-chain variable fragment for recognizing NGcGM3 ganglioside on tumor cells and an antibody, an antibody fragment or a single-chain variable fragment for recognizing a CD3 antigen on human immune effector cells. These bispecific antibodies are characterized in that they are capable of mediating selective cytotoxicity against NGcGM3-positive tumor cells, rather than normal cells capable of expressing the gangliosides, and allow recruitment of not only T lymphocytes but also NKT. The bispecific antibodies of the invention, as well as the nucleic acids encoding them, are useful for the treatment of lymphoproliferative diseases and solid tumors expressing NGcGM3.

The invention provides a method for detecting amino acid in a compound encephalokinin injection by using an LC-MS (Liquid Chromatography-Mass Spectrometry) method, which has the characteristics of simplicity and convenience in operation, and good precision, stability and recovery rate. The method can be used for detecting the content of 13 amino acids in the compound brain peptide injection, including histidine, phenylalanine, lysine, tyrosine, asparagine, methionine, valine, leucine, serine, arginine, proline, alanine and isoleucine. The detection method is high in detection sensitivity and can be applied to internal quality component research, intermediate component control and quality identification of the product. The detection method can also be used for evaluating the inherent quality of the compound encephalokinin injection, further ensuring the stability of the inherent quality of the product and providing technical reference.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

Disclosed is a single-domain antibody specifically binding to ganglioside GD2, which can specifically bind to GD2 glycan. The present application provides a single-domain antibody that can be used for targeting and / or treating several cancers (such as neuroblastoma, glioma, etc.) associated with GD2-overexpressing cells. The present application also relates to a recombinant nucleic acid sequence encoding the above-mentioned single-domain antibody, as well as an expression vector and a host cell.

This invention discloses a chimeric antigen receptor (CAR), microglia expressing the CAR differentiated from human pluripotent stem cells, and their applications. The chimeric antigen receptor CAR provided by this invention is a bisialic acid ganglioside-based chimeric antigen receptor, and its amino acid sequence is shown in SEQ ID NO.1. This invention also provides a method for preparing microglia expressing the CAR differentiated from human pluripotent stem cells, comprising the following steps: infecting human pluripotent stem cells with the lentivirus; screening for positive clones, selecting positive clones for culture and identification; differentiating the human pluripotent stem cells expressing the CAR into microglia, thereby obtaining the microglia expressing the CAR. The microglia expressing the CAR differentiated from human pluripotent stem cells provided by this invention have unique advantages such as non-immunogenicity and no immune rejection issues in human treatment.

Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta-galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta-hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

The invention discloses a sphingolipid ceramide N-deacylase mutant. The mutant is formed by amino acid mutation in sphingolipid ceramide N-deacylase as shown in SEQ ID NO.1, and the amino acid mutation is selected from one or more of mutation of the 232 site Tyr, mutation of the 254 site Asn, mutation of the 416 site Phe and mutation of the 592 site Leu. The invention also discloses application of the mutant in preparation of ganglioside derivative molecules by efficient enzymatic synthesis. The stability of the sphingolipid ceramide N-deacylase SCDase mutant is improved, and the pyrolysis chain temperature Tm of the mutant is improved by 5.79 DEG C compared with that of a wild type; the sphingolipid ceramide N-deacylase SCDase mutant provided by the invention enhances the enzyme preparation efficiency of ganglioside, especially for short-chain fatty acids (carbohydrate chain length lt; and 4) the synthetic activity is improved by more than two times, and the result broadens the practical application value of the SCDase enzyme.

The present invention relates to antibodies directed against ganglioside tumor antigens which can be obtained in Phaeodactylum tricornutum, said antibodies presenting an increased FcRn affinity and an increased direct cytotoxicity activity; their uses as medicament and for cancer treatment more specifically.

The application discloses a blood marker combination and kit for neurodegenerative diseases of lysosome function axis, and relates to the technical field of biomedical detection. The marker combination is composed of seven markers in three categories: glucocerebrosidase and cathepsin D; sphingolipids and gangliosides; and phosphorylated tau-217 protein, neurofilament light chain protein and glial fibrillary acidic protein. The application also provides an in-vitro diagnostic kit containing specific reagents for detecting the above markers, and constructs a risk assessment model based on a logistic regression or random forest algorithm. The marker combination and kit can be used for early screening, differential diagnosis, disease progression prediction and drug efficacy monitoring of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and neurogenic Gaucher disease, and have the advantages of high sensitivity, high specificity and minimally invasive detection.

The application belongs to the technical field of biological medicine, and particularly relates to an immune liposome targeting ganglioside GD2 and mitochondria as well as a preparation method and application thereof. The application couples LX3 and thiolated daratumumab to DSPE-PEG2000 respectively to obtain DSPE-PEG2000-LX3 and DSPE-PEG2000-aGD2, and then is compounded with DSPC and cholesterol to obtain the immune liposome, which has good dispersity, excellent stability and cannot induce cytotoxicity. Cell combination and uptake analysis shows that the immune liposome can specifically target ganglioside GD2 positive tumor cells and then further reach mitochondria thereof. Compared with existing liposomes, the immune liposome provided by the application has double targeting functions of ganglioside GD2 and mitochondria, and can selectively deliver an anti-tumor drug into mitochondria of neuroblastoma cells.

The invention relates to the field of analytical chemistry and the field of lipidomics research, in particular to a method for omics analysis of acidic glycosphingolipids in animal brain tissues. The group analysis method comprises the following steps: firstly, extracting ganglioside and thioglycoside from animal brain tissues, carrying out C18 solid-phase extraction and enrichment, then carrying out qualitative analysis by using Nano-LC-Chip-Q-TOF-MS, carrying out analysis in combination with a QSRR model, and then carrying out quantitative analysis by using Nano-LC-Chip-QQQ-MS. The group analysis method is based on a Chip technology, combines C18 solid-phase extraction segmented enrichment and a QSRR model, greatly avoids ion inhibition and signal interference, has high resolution, high sensitivity and high accuracy, can accurately distinguish isomeride and same-weight elements, remarkably improves the detection efficiency and the structural identification and unknown substance prediction and quantification capability, and has a good application prospect. The defects of low-abundance component loss, narrow dynamic range and the like in the prior art are overcome.

The present invention provides a pharmaceutical-acceptable lipid nanoparticle (LNP) composition for delivering active agents to the bone marrow. The LNP comprises a ganglioside, a cholesterol, a phospholipid, and a cationic or ionizable lipid and exhibits superior transfection efficiency in bone marrow cells relative to other lipid nanoparticles that lack the ganglioside.